NRX Lauds Hopeful New Push for Psychedelic Medications
The White House has issued an Executive Order directing federal agencies to accelerate research and streamline approvals for psychedelic-based...
Oculis Completes Phase 3 Trial for OCS-01 in DME Patients
Oculis has completed the final patient visit in both Phase 3 DIAMOND trials evaluating OCS-01, a high-concentration dexamethasone eye...
Parkinson’s Trial: Crexont Delivers 3+ More “Good On” Hours
Amneal reported positive interim results from its open-label Phase 4 ELEVATE-PD study showing that patients switching to CREXONT, a...
New Data: Nanoprimer Improves DNA Therapy, Reduces Toxicity
Nanobiotix presented new preclinical data at AACR showing that an intravenous “nanoprimer” administered before lipid nanoparticle–delivered recombinant DNA increased...
N-Xera Pharma Gets $10M Milestone Payment From AbbVie Collab
Nxera Pharma has reached a third R&D milestone in its multi-target neurology discovery collaboration with AbbVie, triggering a $10...
Achieve Life Sciences Secures Up To $354M in Private Placement
Achieve Life Sciences has secured up to $354 million to carry its nicotine-dependence franchise through a pivotal inflection point,...
Aligos & Amoytop in Exclusive License Deal for Hepatitis B
Aligos Therapeutics has licensed Greater China rights to its oral HBV capsid assembly modulator, pevifoscorvir sodium (ALG-000184), to Xiamen...
Eurobio Scientific to Acquire CareDx Transplant Lab Division
Eurobio Scientific has signed a definitive agreement to acquire CareDx’s Lab Products division for approximately €145 million in cash,...
First Patient Enrolled in Pivotal Phase 3 BV100 Trial
BioVersys has dosed the first patient in its global pivotal Phase 3 RIV-TARGET trial evaluating BV100, an intravenous rifabutin...
AiCuris’ Pritelivir Granted FDA Priority Review, New Data
The FDA has granted Priority Review to AiCuris’ new drug application for pritelivir, an oral helicase-primase inhibitor for refractory...